26Jun/17

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell … – PR Newswire (press release)

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell …
PR Newswire (press release)
Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as …

and more »

26Jun/17

7 KZN athletes for World Transplant games in Spain | IOL – Independent Online


Independent Online

7 KZN athletes for World Transplant games in Spain | IOL
Independent Online
Seven KwaZulu-Natal athletes – all of whom have received organ transplants – will be representing South Africa in the World Transplant Games which began …
Reena Raju to be India’s first woman participant at the World …Sportskeeda
Reena Raju All Set To Become First Woman To Represent India At …Indiatimes.com

all 4 news articles »

26Jun/17

Blood donation apps are here to help in medical emergencies. But where does the blood really go? – Scroll.in


Scroll.in

Blood donation apps are here to help in medical emergencies. But where does the blood really go?
Scroll.in
Officials at the hospital’s blood bank then told the 25-year-old Siddiqui to try looking on websites or mobile applications for blood donors. Siddiqui, who is doing a post-graduate course in education in Jamia Milia University in Delhi, registered on
New York Blood Center Declares Blood EmergencyPR Newswire (press release)
Benefits of Donating BloodHighTech Caller

all 5 news articles »

26Jun/17

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy – PR Newswire

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy  PR Newswire

RAPPERSWIL, Switzerland, June 26, 2017 /PRNewswire/ — The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with…